Insider Transactions in Q2 2025 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 21
2025
|
Richard Pulik CFO |
BUY
Grant, award, or other acquisition
|
Direct |
141,464
+25.78%
|
-
|
|
Apr 21
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-8.22%
|
$1,000,000
$10.22 P/Share
|
|
Apr 21
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+7.6%
|
$300,000
$3.85 P/Share
|
|
Apr 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$109,450
$10.15 P/Share
|
|
Apr 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.97%
|
$109,450
$10.15 P/Share
|
|
Apr 17
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-0.06%
|
$640
$10.15 P/Share
|
|
Apr 17
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,635
+2.5%
|
-
|
|
Apr 17
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-0.29%
|
$2,760
$10.15 P/Share
|
|
Apr 17
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+1.42%
|
-
|
|
Apr 17
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,847
+4.27%
|
-
|